Latest News

December 19, 2017

Radio Interview: When Should Children be Introduced to Peanut Products?

This week on WRVO Public Radio's Take Care, hosts Lorraine Rapp and Linda Lowen talk with Dr. Gerald Nepom, director of the Immune Tolerance Network, about the ITN's LEAP study and the new guidelines for the introduction of peanut products that might prevent high risk children from developing the allergy. To listen to the full interview, click here.

November 3, 2017

Secondary Outcomes in LEAP-On Participants

In an important follow-up to LEAP-On, which demonstrated that the early introduction of peanut in high-risk infants led to durable prevention of peanut allergy, the investigators now show that early consumption of peanut in infants at high risk of peanut allergy is allergen-specific and does not prevent the development of other allergic disease to other foods, aeroallergens, or allergic reactions to tree nuts and sesame. Furthermore, peanut consumption does not hasten the resolution of eczema or egg allergy.

September 20, 2017

BRAVOS Study for Scleroderma Begins Recruitment

ITN’s BRAVOS (Evaluation of Brentuximab Vedotin for Diffuse Cutaneous System Sclerosis) has opened for recruitment. The goal of this clinical trial is to determine the safety of an investigational study drug, brentuximab vedotin (ADCETRIS®), in diffuse cutaneous systemic sclerosis (dcSSc).

April 12, 2017

Kidney Graft Function and a B Cell Signature

An article published today in the American Journal of Transplantation examined the prevalence of a previously identified genetic signature associated with tolerance in a cohort of kidney transplant patients who may benefit from immunosuppression minimization. A transplant recipients’ lifetime use of immunosuppressive drugs to prevent rejection exposes them to health complications associated with drug toxicity and long-term immunosuppression.

February 14, 2017

Durable Hay Fever Suppression May Require Three Years of Immunotherapy

Immunotherapy that exposes hay-fever patients to increasing amounts of grass pollen over time can be an effective way to reduce severe allergic symptoms in the long term.

February 2, 2017

HALT-MS Therapy Effective for Inducing Long-Term Sustained Remission of MS Through 5 Years After Transplant

In a study appearing online in Neurology, the HALT-MS trial demonstrated that patients with active relapsing-remitting multiple sclerosis (RRMS) showed sustained remission out to 5 years following high dose immunosuppressive therapy combined with autologous hematopoietic cell transplantation (HDIT/HCT).HALT-MS is a phase II clinical trial of HDIT/HCT for patients with RRMS who experienced relapses with loss of neurological function while on MS disease modifying therapy (DMT).

January 27, 2017

Dr. Jerry Nepom receives 2017 George Eisenbarth Award

We are pleased to announce that Dr. Jerry Nepom, Director of the ITN, has received the 2017 George Eisenbarth Award, a prestigious honor in recognition of his career in research for type 1 diabetes (T1D). The award was presented to Dr. Nepom at the international Immunology of Diabetes conference, held in San Francisco in January. The award was established in 2013 upon the death of George Eisenbarth, a pioneer in the field of type 1 diabetes. Dr. Marion Rewers, from the Barbara Davis Center for Childhood Diabetes, presented this award to Dr.

January 5, 2017

New Peanut Allergy Prevention Guidelines Released Based on ITN's LEAP Study Results

An expert panel sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, issued clinical guidelines to aid health care providers in early introduction of peanut-containing foods to infants to prevent the development of peanut allergy.Peanut allergy is a growing health problem for which no treatment or cure exists.

November 18, 2016

New Publication: Partial Exhaustion of CD8 T Cells in Responders to Anti-CD3 Treatment in New-Onset Type 1 Diabetes

Study results suggesting that T cell exhaustion markers may be correlated with treatment response in type 1 diabetes (T1D) patients from the Immune Tolerance Network’s AbATE study were published today in Science Immunology. This research, led by Alice Long, PhD, and Peter Linsley, PhD, at Benaroya Research Institute, used integrated systems biology and flow cytometry approaches to investigate pathways associated with C-peptide stabilization in responders to anti-CD3 treatment.

August 3, 2016

Abatacept in Relapsing-Remitting Multiple Sclerosis

Abatacept (Orencia®; Bristol-Myers Squibb) did not reduce the number of new gadolinium-enhancing Magnetic Resonance Imaging (MRI) lesions in patients with relapsing-remitting multiple sclerosis compared to a placebo after 24 weeks.